Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Embecta Corp. stock logo
EMBC
Embecta
$10.22
+4.1%
$11.14
$9.49
$21.48
$573.91M1.13488,705 shs714,945 shs
Envista Holdings Corporation stock logo
NVST
Envista
$18.92
+0.1%
$17.53
$14.22
$23.00
$3.20B0.992.53 million shs1.93 million shs
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
$58.93
+0.3%
$57.20
$47.04
$103.81
$3.25B1.1838,770 shs676,082 shs
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$132.64
+4.0%
$115.95
$55.00
$177.37
$4.31B2.11.37 million shs734,049 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Embecta Corp. stock logo
EMBC
Embecta
+0.51%-2.19%-8.40%-22.37%-21.50%
Envista Holdings Corporation stock logo
NVST
Envista
+0.13%-0.45%+12.94%+8.37%+8.56%
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
-2.46%-2.75%+2.37%-6.06%-1.97%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
+3.21%-10.16%+2.64%+80.15%-8.28%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Embecta Corp. stock logo
EMBC
Embecta
4.0669 of 5 stars
3.21.03.30.00.03.33.8
Envista Holdings Corporation stock logo
NVST
Envista
3.1463 of 5 stars
2.22.00.03.81.40.01.9
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
2.6009 of 5 stars
3.41.00.00.02.63.30.6
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
1.3115 of 5 stars
1.42.00.00.01.52.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Embecta Corp. stock logo
EMBC
Embecta
2.33
Hold$19.3389.17% Upside
Envista Holdings Corporation stock logo
NVST
Envista
2.33
Hold$20.236.96% Upside
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
2.86
Moderate Buy$90.0052.72% Upside
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.80
Moderate Buy$127.33-4.00% Downside

Current Analyst Ratings Breakdown

Latest EMBC, PRCT, NVST, and TMDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$130.00 ➝ $150.00
6/17/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
6/4/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$125.00 ➝ $145.00
6/3/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/27/2025
Envista Holdings Corporation stock logo
NVST
Envista
Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
5/27/2025
Envista Holdings Corporation stock logo
NVST
Envista
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Outperform$21.00 ➝ $23.00
5/23/2025
Embecta Corp. stock logo
EMBC
Embecta
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$25.00
5/23/2025
Embecta Corp. stock logo
EMBC
Embecta
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.00
5/9/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$125.00 ➝ $130.00
5/9/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$105.00 ➝ $125.00
5/5/2025
Envista Holdings Corporation stock logo
NVST
Envista
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$21.00 ➝ $18.00
(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Embecta Corp. stock logo
EMBC
Embecta
$1.12B0.53$3.48 per share2.94($12.80) per share-0.80
Envista Holdings Corporation stock logo
NVST
Envista
$2.51B1.28$1.66 per share11.38$17.05 per share1.11
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
$224.50M14.52N/AN/A$7.71 per share7.64
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$441.54M10.16$1.71 per share77.51$6.81 per share19.48
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Embecta Corp. stock logo
EMBC
Embecta
$78.30M$0.9011.363.330.624.89%-19.67%12.27%8/8/2025 (Estimated)
Envista Holdings Corporation stock logo
NVST
Envista
-$1.12B-$6.53N/A15.631.20-44.90%4.07%2.25%8/6/2025 (Estimated)
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
-$91.41M-$1.70N/AN/AN/A-36.20%-28.09%-20.02%7/30/2025 (Estimated)
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$35.46M$1.3697.5392.76N/A10.03%21.88%6.15%7/30/2025 (Estimated)

Latest EMBC, PRCT, NVST, and TMDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q2 2025
Embecta Corp. stock logo
EMBC
Embecta
$0.66$0.70+$0.04$0.40$261.77 million$259.00 million
5/8/2025Q1 2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$0.29$0.70+$0.41$0.70$123.39 million$143.54 million
5/1/2025Q1 2025
Envista Holdings Corporation stock logo
NVST
Envista
$0.20$0.24+$0.04$0.10$608.17 million$616.90 million
4/24/2025Q1 2025
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
-$0.49-$0.45+$0.04-$0.45$65.39 million$69.16 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Embecta Corp. stock logo
EMBC
Embecta
$0.605.87%N/A66.67%N/A
Envista Holdings Corporation stock logo
NVST
Envista
N/AN/AN/AN/AN/A
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
N/AN/AN/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
N/AN/AN/AN/AN/A

Latest EMBC, PRCT, NVST, and TMDX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/5/2025
Embecta Corp. stock logo
EMBC
Embecta
quarterly$0.154.51%5/28/20255/28/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Embecta Corp. stock logo
EMBC
Embecta
N/A
2.48
1.83
Envista Holdings Corporation stock logo
NVST
Envista
0.43
2.12
1.82
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
0.13
8.95
7.75
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
1.92
9.10
8.32

Institutional Ownership

CompanyInstitutional Ownership
Embecta Corp. stock logo
EMBC
Embecta
93.83%
Envista Holdings Corporation stock logo
NVST
Envista
N/A
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
89.46%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
99.67%

Insider Ownership

CompanyInsider Ownership
Embecta Corp. stock logo
EMBC
Embecta
0.42%
Envista Holdings Corporation stock logo
NVST
Envista
1.30%
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
17.40%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
7.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Embecta Corp. stock logo
EMBC
Embecta
2,10058.44 million58.20 millionOptionable
Envista Holdings Corporation stock logo
NVST
Envista
12,300169.49 million167.28 millionOptionable
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
43055.33 million45.70 millionOptionable
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
21033.82 million31.46 millionOptionable

Recent News About These Companies

These 24 Stocks Are Ripe for a Short Squeeze

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Embecta stock logo

Embecta NASDAQ:EMBC

$10.22 +0.40 (+4.07%)
Closing price 04:00 PM Eastern
Extended Trading
$10.22 -0.01 (-0.05%)
As of 05:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

Envista stock logo

Envista NYSE:NVST

$18.92 +0.02 (+0.08%)
Closing price 03:59 PM Eastern
Extended Trading
$18.94 +0.03 (+0.14%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

PROCEPT BioRobotics stock logo

PROCEPT BioRobotics NASDAQ:PRCT

$58.93 +0.19 (+0.32%)
Closing price 04:00 PM Eastern
Extended Trading
$58.90 -0.03 (-0.05%)
As of 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

TransMedics Group stock logo

TransMedics Group NASDAQ:TMDX

$132.64 +5.11 (+4.01%)
Closing price 04:00 PM Eastern
Extended Trading
$132.57 -0.07 (-0.05%)
As of 07:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.